New combo therapy aims to control hard-to-treat hodgkin lymphoma
NCT ID NCT05723055
First seen Jan 05, 2026 · Last updated Apr 30, 2026 · Updated 13 times
Summary
This study tests whether adding axatilimab to nivolumab can help control Hodgkin lymphoma that has returned or not responded to prior treatments. About 9 adults who have already tried at least one other therapy, including a PD-1 inhibitor, will receive the combination. The main goal is to see how many people's tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute at the University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.